RALEIGH, NC--(BUSINESS WIRE)--Aug. 8, 2006--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP - News): Total product revenue was $52.9 million for the second quarter of 2006, a year-over-year increase of 51%, compared to $35.1 million for the second quarter of 2005. Total product revenue for the first six months of 2006 was $94.7 million, a year-over-year increase of 48%. XIFAXAN® revenue for the second quarter of 2006 was $10.4 million, a 61% increase compared to the second quarter of 2005, and XIFAXAN revenue for the first six months of 2006 was $17.0 million, an 87% increase compared to the first six months of 2005. Prescription growth over the same comparable time periods was 122% and 135%, respectively.
